28/08/2026 NMPA Approves ATLED (Fanregratinib) for FGFR2+ Intrahepatic Cholangiocarcinoma NMPA Approves ATLED (Fanregratinib) for FGFR2+ Intrahepatic Cholangiocarcinoma (Ref) China’s NMPA has conditionally approved HUTCHMED's ATLED (fanregratinib, HMPL‑453), a selective FGFR1/2/3 inhibitor, for adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions/rearrangements after prior systemic therapy The approval is supp

29/12/2025 HUTCHMED's fanregratinib received priority review status in China for second-line intrahepatic cholangiocarcinoma Genmab discontinued the clinical development of acasunlimab following a portfolio review HUTCHMED's fanregratinib received priority review status in China for second-line intrahepatic cholangiocarcinoma (Ref) China's NMPA accepted and granted priority review status to HUTCHMED Limited's NDA for fanregratinib (FGFR 1/2/3 inhibitor) for the treatment of a